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Scale (KPS), Spitzer QOL-Index, Expanded Disability Status Scale (EDSS), and the 
Hamilton Rating Scale for Depression (HAM-D) were evaluated in terms of: concep-
tual framework; patient, literature and clinician contribution to development; process 
for deriving items; content validity; item reduction; linguistic and cultural adaptation; 
scoring; and reliability, validity, and ability to detect change. RESULTS: The FDA 
discourages the use of CROs for symptoms that can only be known to the patient, 
whereas clinical signs are usually observed and interpreted by the clinician. Despite 
the widespread use of the KPS as a classiﬁcation of functional status in patients with 
cancer, there is little data supporting the development, content validity, and statistical 
measurement properties of the scale. Among other critiques, the EDSS has question-
able inter-rater reliability. Although the Spitzer QOL-index was developed with 
patient input and has documented measurement properties, the use of proxy for QOL/
HRQL evaluations is widely discouraged. The HAM-D is considered the ‘gold stan-
dard’ of depression rating scales with good psychometric properties, but with ques-
tionable content validity. CONCLUSIONS: The suitability of the selected CROs as 
endpoints for regulatory approvals varied widely. CROs are essential and complimen-
tary primary and secondary endpoints for drug evaluations for the purpose of FDA 
regulatory submissions, it is likely that sponsors will face increasing FDA scrutiny of 
CRO endpoints for the purpose of label claims.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Cost Methods
PMC2
REVIEW OF PHARMACOECONOMIC RECOMMENDATIONS FOR THE 
DEFINITION OF A SOCIETAL PERSPECTIVE
Fisher M, Alnwick K
Heron Evidence Development Limited, Luton, UK
OBJECTIVES: To compare the ways pharmacoeconomic (PE) guidelines in European 
and North American countries deﬁne the societal perspective for economic evalua-
tions. METHODS: Full-text country-speciﬁc PE guidelines were obtained via the 
ISPOR website and where possible cross-referenced with Health Technology Assess-
ment (HTA) agency recommendations. The following countries were selected for 
comparison: Belgium, Canada, Finland, France, Italy, Norway, the The Netherlands, 
Portugal and Sweden. The cost categories considered for the societal perspective were 
assessed and compared between country guidelines. RESULTS: PE guidelines from 
eight of the selected countries identiﬁed speciﬁc cost categories for the societal perspec-
tive. Guidelines agreed that the direct costs associated with this perspective included 
costs to the health service, costs to other publicly funded services and costs to patients/
family. Costs of time lost by family/unpaid carers was considered by 6/8 guidelines, 
which differed in assigning the cost as direct or indirect. There were differences in the 
indirect costs considered; costs of time lost by patients was only considered by 2/8 
guidelines. Intangible costs were considered by 4/8 guidelines, although it was gener-
ally accepted that these should be accounted for in the outcome measurement rather 
than through costs. Productivity loss was considered as an indirect cost by nine 
guidelines; however the preferred method of derivation differed between guidelines: 
2/9 guidelines preferred the Friction Cost Method (FCM) and 3/9 guidelines preferred 
the Human Capital Method (HCM). Moreover, there were differing views regarding 
the types of productivity loss to include: Portugal recommended consideration of 
employee-related loss only, whereas Canada also included loss to the employer associ-
ated with hiring new staff. CONCLUSIONS: There are subtle differences between the 
ways the societal perspective is deﬁned by PE guidelines in Europe and North America. 
This should be considered when devising evidence generation activities to support 
economic modelling, and may ultimately impact the outcome of HTA decisions.
PMC3
REVIEW OF COST EFFECTIVENESS ANALYSES THAT INCORPORATE 
NUMBER NEEDED TO TREAT/HARM VALUES
Raisch DW, Nawarskas JJ
University of New Mexico College of Pharmacy, Albuquerque, NM, USA
INTRODUCTION: Number needed to treat/harm (NNT/NNH) values are universally 
understood and applied by clinical decision makers. Therefore providing these values 
alongside cost effectiveness analysis (CEA) results may increase the relevance and 
clarify clinical implications of CEAs to decision makers. OBJECTIVES: To review the 
literature of CEA studies that incorporate NNT/NNH values. METHODS: We 
searched Pub Med using the Mesh term “cost-beneﬁt analysis” and “number needed 
to treat “, “number needed to harm”, “NNT”, or “NNH”. We included CEA studies 
and studies describing relationships between NNT/NNH and quality adjusted life 
years (QALYs) published in English. RESULTS: There were 102 publications identi-
ﬁed. Of these 47 provided both CEA and NNT/NNH results. There were 43 (91.5%) 
studies published in clinician-focused practice journals, 2 (4.3%) in policy journals, 
and 2 (4.3%) in economic journals. The CEA incorporated NNT/NNH directly as 
part of the CEA ratio in 23 (48.9%) studies and CEA was separately stated from 
NNT/NNH in 14 (29.8%) studies. The CEA was expressed as cost per QALY dis-
tinctly from NNT/NNH in 10 (21.3%). The focuses of the articles were disease 
treatments in 28 (59.5%) studies, disease prevention in 15 (31.9%), and patient educa-
tion or disease management in 2 (4.3%) each. Also, there were 4 studies regarding 
relationships between NNT/NNH and QALYs. CONCLUSIONS: We found that the 
majority of articles incorporating NNT/NNH into CEA were published in clinical 
practice journals and most involved comparisons of speciﬁc disease treatments. Incor-
porating NNT/NNH into CEA results may improve relevance to clinical decision-
making, but further research is needed regarding how they are best integrated. One 
alternative may include weighting NNT/NNH values for different outcomes in terms 
of QALYs.
PMC4
THE DERIVATION OF TRICARE SPECIFIC CONSUMER PRICE INDICES 
FOR PRESCRIPTION DRUGS
Summers CR
TRICARE Management Activity, Falls Church, VA, USA
OBJECTIVES: One of the chronic issues in pharmaceutical utilization management is 
the dearth of accurate price benchmarks available to establish pharmacy-pricing 
performance. This paucity of appropriate benchmarks is further complicated for 
organizations, such as TRICARE, who have reason to believe that their demographics 
and hence disease proﬁles yield atypical prescription drug market baskets. Thus, to 
obtain an accurate assessment of organizational performance, organization-speciﬁc 
indices need to be developed. METHODS: A unique approach to developing organiza-
tion speciﬁc benchmarks is underway in a joint venture between the TRICARE 
Pharmaceutical Operations Directorate (POD) and the US Bureau of Labor Statistics 
(BLS). The primary method is to match retail pricing information provided by BLS 
and portfolio information provided by TRICARE to construct organization speciﬁc 
benchmarks that can be tracked over time. Variables from the Consumer Price Index 
for Prescription Drugs (CPI-Rx) are transferred to the POD as speciﬁed in an inter-
governmental memorandum of understanding. To form an overall TRICARE-Rx 
index for a speciﬁc month, all TRICARE prescription data are aggregated by speciﬁc 
drug and the number of prescriptions is computed for each drug for speciﬁc month 
using a ﬁle extracted from the Pharmacy Data Transaction Service (PDTS). CPI-Rx 
prices are then aggregated by same list of unique drugs used in the TRICARE sample 
then averaged in a separate ﬁle. The ﬁles are then merged using NDC codes as the 
key. The index is computed using the average CPI-Rx price for each speciﬁc drug 
multiplied by the TRICARE N for the corresponding drugs then averaged. CONCLU-
SIONS: TRICARE spends roughly $7.5 Billion annually for prescription drugs. With 
the development of these indices, we can better gauge our cost containment priorities 
and efforts. This will help us determine if increases in costs are due to general drug 
price inﬂation speciﬁc to our unique market basket of drugs.
PMC5
VALIDATING A WEB-BASED INCREMENTAL COST-EFFECTIVENESS 
SOFTWARE PROGRAM THAT USES A MARKOV TRANSITION 
PROBABILITY MATRIX ANALYSIS MODEL
McGhan W, Zaveri V, Willey VJ, Gohil N
University of the Sciences in Philadelphia, Philadelphia, PA, USA
OBJECTIVES: Commercial software can be expensive when conducting pharmaco-
economic analyses. We developed a free web-based software program, which incor-
porates Markov transition probabilities to compare the cost-effectiveness of any two 
treatments. The web-based software program was based on the model described in a 
decision modeling for health economic evaluation textbook, edited by A. Briggs. This 
Markov web-based software program calculates the incremental cost-effectiveness 
based on Markov matrices using multi-state transition probabilities, along with cor-
responding Markov state costs and utilities and graphically displays the results, using 
JavaScript algorithms and is available free at www.healthstrategy.com. The variable 
inputs for two treatment options include state transition probabilities, number of 
cycles, cost per state, and utility per state. The software creates a plot of incremental 
costs versus incremental utilities in cost-effectiveness quadrants; and with death as an 
absorbing state, also graphs life expectancy curves for two treatment comparisons. 
The objective of this study was to validate this free web-based software. METHODS: 
The Excel spreadsheet structure and data downloaded from the web for the speciﬁc 
example described in the modeling textbook were used as the reference case. 
RESULTS: For the example used, considering four transition states for each therapy 
option, and 20 cycles with no discounting, the MS Excel spreadsheet model versus 
the web-based JavaScript software compared as follows: average incremental US dollar 
costs: ($67701 vs. $67853), average incremental utility: (5.89 vs. 5.90) and average 
incremental cost-effectiveness ratio:($11500 vs. $11494). CONCLUSIONS: This free 
web-based Markov matrix JavaScript program gives similar results as the MS Excel 
spreadsheet model. With this free software, the user can input their own therapy 
parameters, and generate incremental costs, incremental utilities, life expectancy 
curves, and incremental cost effectiveness ratios. This free web-based software has 
potential beneﬁt as an educational tool for students and health professionals interested 
in exploring these analytical approaches.
PMC6
USE OF CLINICAL SIMULATION CENTERS TO CONDUCT PATIENT-
CENTERED TIME-AND-MOTION SIMULATIONS AS A BASIS FOR 
ECONOMIC ANALYSIS
Nickman N, Haak S, Kim J
University of Utah, Salt Lake City, UT, USA
BACKGROUND: Patient-centered professional practice and technology assessment 
research performed in health professional schools’ clinical simulation centers is a novel 
concept. Opportunities can be created for multidisciplinary collaboration relative to 
evaluation of medication regimen and device complexity. Micro-level costs can then 
be assigned and economic analysis conducted in a more precise fashion than in tradi-
tional clinical trials or database outcomes analysis. METHODS: One university’s 
pharmacy and nursing schools’ clinical simulation centers were used in two separate 
projects to conduct time-and-motion and activity-based costing analyses speciﬁc to 
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work-related activities consisting of nurse, pharmacist, and/or patient medication 
dispensing, preparation, administration and/or storage. Projects consisted of time and 
cost differences related to 1) three proton pump inhibitor dosage forms and seven 
administration methods, and 2) seven recombinant human growth hormone adminis-
tration methods/devices. Performance-based time data were then used to determine 
personnel/patient opportunity time and supply costs associated with different forms 
of medications and delivery devices. Simulations were developed and used to hold 
independent variables constant so only observed differences between medications and/
or device types could be assessed. Statistical and micro-economic cost analyses were 
conducted speciﬁc to each type of medication and/or device. RESULTS: Processes and 
results show two detailed examples as case studies of how simulation-based research 
may be used to assess health care processes at the micro level. The advantages of isolat-
ing processes of interest from the day-to-day complexity of patient care are demon-
strated. Simulations may also represent an efﬁcient assessment alternative of health 
care processes at the micro level with potential for projection to the macro level as 
compared to live, direct observation, cost-intensive, patient-centered care practice 
evaluations. CONCLUSIONS: Simulation-based time-and-motion and activity-based 
cost analyses allowed detailed micro-level time, workload, and supply evaluations that 
may be projected to the macro level. Professional schools’ simulation laboratories offer 
appropriate settings for such studies.
PMC7
ESTIMATING TIME-PROFILED ECONOMIC BURDEN OF ILLNESS
Cao Z1, Song X1, Mark T2
1Thomson Reuters, Cambridge, MA, USA, 2Thomson Reuters, Washington, DC, USA
OBJECTIVES: Demonstrate a technique to characterize the economic burden of illness 
over time, correcting for censoring bias and controlling for difference in baseline 
characteristics between comparison groups. A sample of patients with diagnosis of 
disease A in 2004–2008 were extracted from MarketScan® databases and followed 
to death, disenrollment, or December 31, 2008 (cases). The ﬁrst diagnosis date was 
the index date. Enrollees without disease A were extracted as controls. Their index 
dates were assigned based on the distribution of index dates of cases. METHODS: 
First, Kaplan-Meier estimates for the probability of remaining in the data were calcu-
lated by month and disease status. Failure event was death or disenrollment. Censoring 
event was termination of MarketScan contract or end of study period. Next, total 
health care costs were estimated using generalized linear models (GLM) on the sub-
sample of survivors/enrollees in each month, controlling for disease status, patient 
demographic and clinical characteristics. Adjusted costs were calculated by month and 
disease status using the regression estimates and average characteristics. Estimated 
total costs during the whole follow-up period were the sum of probability of remaining 
in the data multiplied by regression-adjusted costs in each month. RESULTS: At the 
end of year 1, 40.5% of cases deceased or disenrolled from insurance compared to 
13.6% of controls (p < 0.001); at the end of year 4 these ﬁgures were 76.4% and 
30.5%, respectively (p < 0.001). GLM results indicated signiﬁcantly higher cost among 
the group with disease A in each month during follow-up. The adjusted costs based 
on average characteristics was $86,592 for cases vs. $6,178 for controls in the ﬁrst 
year and $151,077 vs. $21,890 in the ﬁrst 4 years. CONCLUSIONS: In studies with 
variable-length follow-up, an estimator combining the survivor probability and regres-
sion-adjusted cost is more robust to censoring bias, and better depicts the economic 
burden of illness over time.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Databases & 
Management Methods
PMC8
THE EFFECT OF LENGTH OF OBSERVATION AND CLAIMS DATA TYPE 
ON ESTIMATES OF COMORBIDITIES AMONG MEDICAID BENEFICIARIES
Banahan III BF, Pace PF
University of Mississippi, Oxford, MS, USA
OBJECTIVES: Researchers frequently use claims data to create comorbidity measures. 
The objective of this project was to examine how the number of months of observation 
data and the type of claims data can affect identiﬁcation of comorbidities. METHODS: 
Inpatient (IP) and outpatient (OT) claims data were used to identify comorbidities for 
beneﬁciaries enrolled in a state Medicaid program. Beneﬁciaries were included if they 
were enrolled for a continuous 24-month period between January 2002 and December 
2004. Data were used to identify the ﬁrst month in which an ICD-9 code appeared 
for each of the 17 comorbidities included in the Charlson Comorbidity Index. The 
D’Hoore scoring system was used to identify ICD-9 codes associated with each 
comorbidity. Results from the IP and OT claims were combined to create overall 
comorbidity measures. RESULTS: The study included a total of 618,337 unique 
patients. The OT claims could identify almost all comorbidities (low of 88.0% for 
myocardial infarctions, high of 99.5% for diabetes). IP claims were much less likely 
to identify comorbidities (low of 11.5% for connective tissue disease, high of 45.7% 
for myocardial infarction). At 12 months, less than half of the beneﬁciaries with 
comorbid events during the 24-month period had been identiﬁed for dementia 
(43.9%), cerobrovascular disease (45.6%), peripheral vascular disease (45.6%), and 
myocardial infarction (48.4%). In contrast, 78.1% of patients with diabetes events 
and 69.0% of patients with chronic pulmonary disease events had been identiﬁed at 
12 months. CONCLUSIONS: The percentage of patients ascribed comorbidities will 
vary signiﬁcantly depending on the number of observation months. Obviously, the 
incidence rate for new events/diagnoses contributes to the increase over time. However, 
researchers must be careful since some comorbidities may not be associated with 
frequent enough physician ofﬁce visits to accurately detect existing comorbidities when 
the number of observation months is short.
PMC9
DATA SCAFFOLDING: A PRAGMATIC APPROACH TO STRUCTURING A 
LITERATURE REVIEW SPREADSHEET TO MAXIMIZE INFORMATION, 
FACILITATE REVIEW AND SUPPORT ANALYSIS
Ogden K1, Hansen R1, Rattana S2, Neil N1
1ICON Clinical Research, Lifecycle Sciences Group, San Francisco, CA, USA, 2ICON Clinical 
Research, Lifecycle Sciences Group, Chicago, IL, USA
OBJECTIVES: Clinical literature reviews, especially systematic reviews, require the 
management and evaluation of large amounts of bibliographic data. Although the 
methodology for performing reviews is well documented, few sources share practical 
guidance on how to electronically manage citation data in order to efﬁciently inven-
tory, organize, and assess published material. Spreadsheet tools (e.g., Excel®) give 
researchers unparalleled freedom to manipulate a large volume of information culled 
from source databases (e.g., MEDLINE®); however, many researchers lack a blueprint 
for structuring their data to facilitate review. METHODS: We describe a process of 
erecting “data scaffolding” that is critical to transforming a literature review spread-
sheet into an agile, manipulable source of information that can triage, sort, and report 
on materials retrieved for review. RESULTS: Using a sample of literature data pulled 
from PubMed®, we describe several ideas for adding key structural components to a 
spreadsheet of citations that bring ﬂexibility and functionality to the processes of 
article review and analysis. In doing so, we also describe the hows and whys of 
spreadsheet design to facilitate literature review, such as the importance of the spread-
sheet layout; the addition of ﬂag ﬁelds to use medical subject headings or key words 
to easily sort, organize, identify/retrieve, navigate, and summarize citations; and ways 
of leveraging built-in spreadsheet features such as autoﬁlters, freeze-panes, and sub-
totals that can greatly facilitate the inventory and management of large volumes of 
citation data to support literature reviews. CONCLUSIONS: In an era of increasing 
volumes of published literature and the proliferation of rigorous, formalized, system-
atic and non-systematic reviews, researchers must adapt to growing demands. Existing 
spreadsheet tools can be leveraged to effectively meet these demands, in ways that not 
only provide for greater efﬁciency but in ways that may result in enhanced research 
capabilities.
PMC10
RATIONALE AND DEVELOPMENT OF AN ONLINE DIRECTORY OF 
DATABASE PROFILES FOR PHARMACOEPIDEMIOLOGY, OUTCOMES, 
AND POPULATION RESEARCH
Kamani SA, Goehring Jr EL, Singh VP, Nguyen-Khoa BA, Kapasi AJ, Jones JK
DGI, Inc., Arlington, VA, USA
OBJECTIVES: Large epidemiology studies using population databases are in high 
demand in the current health care environment. Simultaneously, the number of health 
care databases available for research has risen considerably. Increasingly complex 
research questions require population researchers to be more aware of the availability 
and details of databases worldwide. To address this growing need, a web-based direc-
tory with detailed proﬁles of population research databases was developed. 
METHODS: B.R.I.D.G.E. TO DATASM (Beneﬁt-Risk Information for Drug Evalua-
tions) is an advanced version of the original R.A.D.A.R. (Risk Assessment of Drugs 
Analysis & Response) books (1990s; 200+ database proﬁles), and the subsequent 
BRIDGE On-Line version (1999–2003). Over a 20-month period, we convened an 
advisory board, re-branded the website, and updated content. A web development 
ﬁrm built the infrastructure of bridgetodata.org. Content was developed by assessing 
existing database proﬁles and performing extensive literature reviews. A database 
proﬁle template was created with 75 common ﬁelds covering the following categories: 
population type, demographics, physician, drug, diagnosis, procedure, economic, vali-
dation, linkage, and administrative data. We received advisory board feedback at 
multiple stages, and database managers were contacted for listing authorization and 
content approval. A quality assurance process involved systematic review of each 
proﬁle by the primary editor, DGI staff, and database managers. RESULTS: The site 
was launched in November 2009 with 50 database proﬁles from USA, Europe, and 
Asia. It features a web interface designed to perform database searches by ﬁeld type 
and to allow side-by-side comparison of multiple databases. Limitations included a 
short timeline and budgetary constraints. CONCLUSIONS: Development of a web-
based directory of population research database proﬁles will enable the identiﬁcation 
of appropriate databases for pharmacoepidemiologic, economic, and health services 
research. Other applications may include serving as an educational tool and as a model 
for developing new health care databases.
PMC11
CAP DATABASE—PROVISION OF OUTPATIENT PROCEDURE DATA IN 
A UNIFIED, STANDARDIZED LANGUAGE
Endel G, Weisser A
Head Association of the Austrian Social Insurance Companies, Vienna, Austria
OBJECTIVES: Due to the heterogeneous health care environment in Austria, data 
about procedures performed in outpatient clinics, ambulatories and in the outpatient 
sector have not been collected in a standardized language. However, this data is crucial 
for planning processes and health services provision. Therefore, the Ministry of Health 
in collaboration with the Austrian Social Security and 3 of 9 Federal States initiated 
